Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen's Q3 Revenues Rise 64 Percent

NEW YORK (GenomeWeb News) – Nanogen today reported revenue growth of 64 percent as the firm prepares to merge with French diagnostics firm Elitech Group.
Nanogen brought in total revenues of $13.8 million for the three-month period ended Sept. 30, compared with $8.4 million in the third quarter of 2007. Its product sales increased to $7.8 million from $5.5 million year over year, while its license fees slipped to $1.5 million from $1.8 million. The firm’s contracts and grants revenues increased sharply to $4.4 million from $1 million.
Nanogen cut its R&D expenses 36 percent to $4.8 million from $7.5 million, and its SG&A spending declined 13 percent to $8 million from $9.2 million.
The company posted a net loss of $6 million, or $.08 per share, compared with a net loss of $901,000, or $.01 per share, for the third quarter of 2007. Last year’s Q3 results included a $12.7 million gain tied to its investment in Finnish firm Jurilab.
Nanogen finished the quarter with $1.7 million in cash and cash equivalents.
Nanogen Chairman and CEO Howard Birndorf said in a statement that the firm’s “continuing improvement in business operations, combined with the planned merger with Elitech in early 2009, will complete the transformation of Nanogen into a profitable, global in vitro diagnostics company.”
The firm announced in August its planned merger into Elitech Group. Under the terms of the agreement, Nanogen said that Elitech shareholders are expected to receive shares of Nanogen common stock valued at €66.5 million ($98.5 million).

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.